Close Menu

Interpace Diagnostics

With the approval of its ThyraMIR diagnostic assay, the firm said that physicians will have access to its thyroid product suite across several specimen types.

For full-year 2018 the firm's revenues rose 38 percent to $21.9 million from $15.9 million a year ago.

A brief recap of Diagnostics news the week of Feb 1, 2019: Ambry Genetics, Quotient, Angle, PathAI, C2N Diagnostics, Interpace Diagnostics

The firm will use the proceeds for working capital, capital payments, business development, research and development payments, and technology and business acquisitions.

The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.

Quest Diagnostics and Oxford Immunotec Global announced this week that Quest has completed its previously announced acquisition of Oxford Immunotec's US laboratory services business.

OncoDNA said this week that new guidelines from the Spanish Society of Pathology and the Spanish Society of Medical Oncology now endorse genomic testing to identify cancers of unknown primary origin using tools like OncoDNA's OncoDEEP product — a combined DNA and protein assay performed on solid tumor samples.

The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.

Pages